Cargando…

A Third Dose COVID-19 Vaccination in Allogeneic Hematopoietic Stem Cell Transplantation Patients

We previously reported that a second dose of BNT162b2 was safe and effective for allogeneic hematopoietic stem cell transplantation (HSCT) patients. Here, we investigated the safety and efficacy of a third dose of COVID-19 mRNA vaccine in allogeneic HSCT patients. Antibody titers against the S1 spik...

Descripción completa

Detalles Bibliográficos
Autores principales: Watanabe, Marika, Yakushijin, Kimikazu, Funakoshi, Yohei, Ohji, Goh, Ichikawa, Hiroya, Sakai, Hironori, Hojo, Wataru, Saeki, Miki, Hirakawa, Yuri, Matsumoto, Sakuya, Sakai, Rina, Nagao, Shigeki, Kitao, Akihito, Miyata, Yoshiharu, Koyama, Taiji, Saito, Yasuyuki, Kawamoto, Shinichiro, Yamamoto, Katsuya, Ito, Mitsuhiro, Murayama, Tohru, Matsuoka, Hiroshi, Minami, Hironobu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9695068/
https://www.ncbi.nlm.nih.gov/pubmed/36366338
http://dx.doi.org/10.3390/vaccines10111830
_version_ 1784837964719718400
author Watanabe, Marika
Yakushijin, Kimikazu
Funakoshi, Yohei
Ohji, Goh
Ichikawa, Hiroya
Sakai, Hironori
Hojo, Wataru
Saeki, Miki
Hirakawa, Yuri
Matsumoto, Sakuya
Sakai, Rina
Nagao, Shigeki
Kitao, Akihito
Miyata, Yoshiharu
Koyama, Taiji
Saito, Yasuyuki
Kawamoto, Shinichiro
Yamamoto, Katsuya
Ito, Mitsuhiro
Murayama, Tohru
Matsuoka, Hiroshi
Minami, Hironobu
author_facet Watanabe, Marika
Yakushijin, Kimikazu
Funakoshi, Yohei
Ohji, Goh
Ichikawa, Hiroya
Sakai, Hironori
Hojo, Wataru
Saeki, Miki
Hirakawa, Yuri
Matsumoto, Sakuya
Sakai, Rina
Nagao, Shigeki
Kitao, Akihito
Miyata, Yoshiharu
Koyama, Taiji
Saito, Yasuyuki
Kawamoto, Shinichiro
Yamamoto, Katsuya
Ito, Mitsuhiro
Murayama, Tohru
Matsuoka, Hiroshi
Minami, Hironobu
author_sort Watanabe, Marika
collection PubMed
description We previously reported that a second dose of BNT162b2 was safe and effective for allogeneic hematopoietic stem cell transplantation (HSCT) patients. Here, we investigated the safety and efficacy of a third dose of COVID-19 mRNA vaccine in allogeneic HSCT patients. Antibody titers against the S1 spike protein were measured using the QuaResearch COVID-19 Human IgM IgG ELISA kit. The previous study included 25 allogeneic HSCT patients who received two doses of BNT162b2. Following the exclusion of three patients because of the development of COVID-19 (n = 2) and loss to follow-up (n = 1), the study evaluated 22 allogeneic HSCT patients who received a third dose of COVID-19 mRNA vaccine (BNT162b2 [n = 15] and mRNA-1273 [n = 7]). Median age at the time of the first vaccination was 56 (range, 23–71) years. Five patients were receiving immunosuppressants at the third vaccination, namely calcineurin inhibitors (CI) alone (n = 1), steroids alone (n = 2), or CI combined with steroids (n = 2). Twenty-one patients (95%) seroconverted after the third dose. None of our patients had serious adverse events, new-onset graft-versus-host disease (GVHD), or GVHD exacerbation after vaccination. A third dose of the BNT162b2 and mRNA-1273 COVID-19 vaccines was safe and effective for allogeneic HSCT patients.
format Online
Article
Text
id pubmed-9695068
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96950682022-11-26 A Third Dose COVID-19 Vaccination in Allogeneic Hematopoietic Stem Cell Transplantation Patients Watanabe, Marika Yakushijin, Kimikazu Funakoshi, Yohei Ohji, Goh Ichikawa, Hiroya Sakai, Hironori Hojo, Wataru Saeki, Miki Hirakawa, Yuri Matsumoto, Sakuya Sakai, Rina Nagao, Shigeki Kitao, Akihito Miyata, Yoshiharu Koyama, Taiji Saito, Yasuyuki Kawamoto, Shinichiro Yamamoto, Katsuya Ito, Mitsuhiro Murayama, Tohru Matsuoka, Hiroshi Minami, Hironobu Vaccines (Basel) Brief Report We previously reported that a second dose of BNT162b2 was safe and effective for allogeneic hematopoietic stem cell transplantation (HSCT) patients. Here, we investigated the safety and efficacy of a third dose of COVID-19 mRNA vaccine in allogeneic HSCT patients. Antibody titers against the S1 spike protein were measured using the QuaResearch COVID-19 Human IgM IgG ELISA kit. The previous study included 25 allogeneic HSCT patients who received two doses of BNT162b2. Following the exclusion of three patients because of the development of COVID-19 (n = 2) and loss to follow-up (n = 1), the study evaluated 22 allogeneic HSCT patients who received a third dose of COVID-19 mRNA vaccine (BNT162b2 [n = 15] and mRNA-1273 [n = 7]). Median age at the time of the first vaccination was 56 (range, 23–71) years. Five patients were receiving immunosuppressants at the third vaccination, namely calcineurin inhibitors (CI) alone (n = 1), steroids alone (n = 2), or CI combined with steroids (n = 2). Twenty-one patients (95%) seroconverted after the third dose. None of our patients had serious adverse events, new-onset graft-versus-host disease (GVHD), or GVHD exacerbation after vaccination. A third dose of the BNT162b2 and mRNA-1273 COVID-19 vaccines was safe and effective for allogeneic HSCT patients. MDPI 2022-10-29 /pmc/articles/PMC9695068/ /pubmed/36366338 http://dx.doi.org/10.3390/vaccines10111830 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Brief Report
Watanabe, Marika
Yakushijin, Kimikazu
Funakoshi, Yohei
Ohji, Goh
Ichikawa, Hiroya
Sakai, Hironori
Hojo, Wataru
Saeki, Miki
Hirakawa, Yuri
Matsumoto, Sakuya
Sakai, Rina
Nagao, Shigeki
Kitao, Akihito
Miyata, Yoshiharu
Koyama, Taiji
Saito, Yasuyuki
Kawamoto, Shinichiro
Yamamoto, Katsuya
Ito, Mitsuhiro
Murayama, Tohru
Matsuoka, Hiroshi
Minami, Hironobu
A Third Dose COVID-19 Vaccination in Allogeneic Hematopoietic Stem Cell Transplantation Patients
title A Third Dose COVID-19 Vaccination in Allogeneic Hematopoietic Stem Cell Transplantation Patients
title_full A Third Dose COVID-19 Vaccination in Allogeneic Hematopoietic Stem Cell Transplantation Patients
title_fullStr A Third Dose COVID-19 Vaccination in Allogeneic Hematopoietic Stem Cell Transplantation Patients
title_full_unstemmed A Third Dose COVID-19 Vaccination in Allogeneic Hematopoietic Stem Cell Transplantation Patients
title_short A Third Dose COVID-19 Vaccination in Allogeneic Hematopoietic Stem Cell Transplantation Patients
title_sort third dose covid-19 vaccination in allogeneic hematopoietic stem cell transplantation patients
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9695068/
https://www.ncbi.nlm.nih.gov/pubmed/36366338
http://dx.doi.org/10.3390/vaccines10111830
work_keys_str_mv AT watanabemarika athirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients
AT yakushijinkimikazu athirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients
AT funakoshiyohei athirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients
AT ohjigoh athirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients
AT ichikawahiroya athirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients
AT sakaihironori athirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients
AT hojowataru athirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients
AT saekimiki athirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients
AT hirakawayuri athirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients
AT matsumotosakuya athirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients
AT sakairina athirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients
AT nagaoshigeki athirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients
AT kitaoakihito athirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients
AT miyatayoshiharu athirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients
AT koyamataiji athirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients
AT saitoyasuyuki athirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients
AT kawamotoshinichiro athirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients
AT yamamotokatsuya athirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients
AT itomitsuhiro athirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients
AT murayamatohru athirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients
AT matsuokahiroshi athirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients
AT minamihironobu athirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients
AT watanabemarika thirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients
AT yakushijinkimikazu thirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients
AT funakoshiyohei thirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients
AT ohjigoh thirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients
AT ichikawahiroya thirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients
AT sakaihironori thirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients
AT hojowataru thirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients
AT saekimiki thirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients
AT hirakawayuri thirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients
AT matsumotosakuya thirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients
AT sakairina thirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients
AT nagaoshigeki thirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients
AT kitaoakihito thirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients
AT miyatayoshiharu thirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients
AT koyamataiji thirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients
AT saitoyasuyuki thirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients
AT kawamotoshinichiro thirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients
AT yamamotokatsuya thirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients
AT itomitsuhiro thirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients
AT murayamatohru thirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients
AT matsuokahiroshi thirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients
AT minamihironobu thirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients